A citation-based method for searching scientific literature

Beate Bittner, Wolfgang Richter, Johannes Schmidt. BioDrugs 2018
Times Cited: 104







List of co-cited articles
430 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Subcutaneous delivery of monoclonal antibodies: How do we get there?
Margarida Viola, Joana Sequeira, Raquel Seiça, Francisco Veiga, João Serra, Ana C Santos, António J Ribeiro. J Control Release 2018
65
30

Subcutaneous absorption of biotherapeutics: knowns and unknowns.
Wolfgang F Richter, Björn Jacobsen. Drug Metab Dispos 2014
112
19


Mechanistic determinants of biotherapeutics absorption following SC administration.
Wolfgang F Richter, Suraj G Bhansali, Marilyn E Morris. AAPS J 2012
167
16


Subcutaneous Injection Volume of Biopharmaceuticals-Pushing the Boundaries.
Roman Mathaes, Atanas Koulov, Susanne Joerg, Hanns-Christian Mahler. J Pharm Sci 2016
64
23

Accelerating the development of novel technologies and tools for the subcutaneous delivery of biotherapeutics.
David S Collins, Manuel Sánchez-Félix, Advait V Badkar, Randall Mrsny. J Control Release 2020
23
65



Evaluation of the impact of viscosity, injection volume, and injection flow rate on subcutaneous injection tolerance.
Cecile Berteau, Orchidée Filipe-Santos, Tao Wang, Humberto E Rojas, Corinne Granger, Florence Schwarzenbach. Med Devices (Auckl) 2015
49
26

Challenges in the development of high protein concentration formulations.
Steven J Shire, Zahra Shahrokh, Jun Liu. J Pharm Sci 2004
528
12

Optimizing the Bioavailability of Subcutaneously Administered Biotherapeutics Through Mechanochemical Drivers.
D S Collins, L C Kourtis, N R Thyagarajapuram, R Sirkar, S Kapur, M W Harrison, D J Bryan, G B Jones, J M Wright. Pharm Res 2017
22
45

Subcutaneous administration of biotherapeutics: current experience in animal models.
Thomas A McDonald, Monica L Zepeda, Michael J Tomlinson, Walter H Bee, Inge A Ivens. Curr Opin Mol Ther 2010
78
12

Tolerability of High-Volume Subcutaneous Injections of a Viscous Placebo Buffer: A Randomized, Crossover Study in Healthy Subjects.
Clapton Dias, Bassam Abosaleem, Caroline Crispino, Bing Gao, Adam Shaywitz. AAPS PharmSciTech 2015
27
37

Subcutaneous delivery of biotherapeutics: challenges at the injection site.
Joana A D Sequeira, Ana C Santos, João Serra, Catarina Estevens, Raquel Seiça, Francisco Veiga, António J Ribeiro. Expert Opin Drug Deliv 2019
16
62

Subcutaneous Injection of Drugs: Literature Review of Factors Influencing Pain Sensation at the Injection Site.
Iris Usach, Rafael Martinez, Teodora Festini, José-Esteban Peris. Adv Ther 2019
46
21

Intravenous versus Subcutaneous Drug Administration. Which Do Patients Prefer? A Systematic Review.
Kelly L Stoner, Helena Harder, Lesley J Fallowfield, Valerie A Jenkins. Patient 2014
54
16

Subcutaneous drug delivery: An evolving enterprise.
Graham B Jones, David S Collins, Michael W Harrison, Nagarajan R Thyagarajapuram, Justin M Wright. Sci Transl Med 2017
30
30

A time and motion study of subcutaneous versus intravenous trastuzumab in patients with HER2-positive early breast cancer.
Erwin De Cock, Xavier Pivot, Nik Hauser, Sunil Verma, Persefoni Kritikou, Douglas Millar, Ann Knoop. Cancer Med 2016
50
18

High-concentration protein formulations: How high is high?
Patrick Garidel, Alexander B Kuhn, Lars V Schäfer, Anne R Karow-Zwick, Michaela Blech. Eur J Pharm Biopharm 2017
64
14


Time Savings with Rituximab Subcutaneous Injection versus Rituximab Intravenous Infusion: A Time and Motion Study in Eight Countries.
Erwin De Cock, Persefoni Kritikou, Mariana Sandoval, Sunning Tao, Christof Wiesner, Angelo Michele Carella, Charles Ngoh, Tim Waterboer. PLoS One 2016
48
16


Impact of Injection Speed, Volume, and Site on Pain Sensation.
Eric Zijlstra, Johannes Jahnke, Annelie Fischer, Christoph Kapitza, Thomas Forst. J Diabetes Sci Technol 2018
26
30

A recombinant human enzyme for enhanced interstitial transport of therapeutics.
L H Bookbinder, A Hofer, M F Haller, M L Zepeda, G-A Keller, J E Lim, T S Edgington, H M Shepard, J S Patton, G I Frost. J Control Release 2006
181
8

Comparison of subcutaneous and intravenous administration of trastuzumab: a phase I/Ib trial in healthy male volunteers and patients with HER2-positive breast cancer.
Chris Wynne, Vernon Harvey, Christian Schwabe, Devonie Waaka, Christine McIntyre, Beate Bittner. J Clin Pharmacol 2013
83
9


Subcutaneous drug delivery and the role of the lymphatics.
Danielle N McLennan, Christopher J H Porter, Susan A Charman. Drug Discov Today Technol 2005
126
7

Overview of Antibody Drug Delivery.
Sahar Awwad, Ukrit Angkawinitwong. Pharmaceutics 2018
56
12

Subcutaneous Trastuzumab for HER2-positive Breast Cancer - Evidence and Practical Experience in 7 German Centers.
C Jackisch, V Müller, P Dall, R Neumeister, T-W Park-Simon, A Ruf-Dördelmann, S Seiler, H Tesch, B Ataseven. Geburtshilfe Frauenheilkd 2015
26
26


Understanding Subcutaneous Tissue Pressure for Engineering Injection Devices for Large-Volume Protein Delivery.
Diane V Doughty, Corbin Z Clawson, William Lambert, J Anand Subramony. J Pharm Sci 2016
19
36

Subcutaneous delivery of daratumumab in relapsed or refractory multiple myeloma.
Saad Z Usmani, Hareth Nahi, Maria-Victoria Mateos, Niels W C J van de Donk, Ajai Chari, Jonathan L Kaufman, Philippe Moreau, Albert Oriol, Torben Plesner, Lotfi Benboubker,[...]. Blood 2019
55
12

Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial.
Maria-Victoria Mateos, Hareth Nahi, Wojciech Legiec, Sebastian Grosicki, Vladimir Vorobyev, Ivan Spicka, Vania Hungria, Sibirina Korenkova, Nizar Bahlis, Max Flogegard,[...]. Lancet Haematol 2020
94
7

The therapeutic monoclonal antibody market.
Dawn M Ecker, Susan Dana Jones, Howard L Levine. MAbs 2015
728
6

Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study.
Xavier Pivot, Joseph Gligorov, Volkmar Müller, Peter Barrett-Lee, Sunil Verma, Ann Knoop, Giuseppe Curigliano, Vladimir Semiglazov, Guillermo López-Vivanco, Valerie Jenkins,[...]. Lancet Oncol 2013
130
6

Formulation and manufacturability of biologics.
Steven J Shire. Curr Opin Biotechnol 2009
184
6

Efficacy and safety of subcutaneous rituximab versus intravenous rituximab for first-line treatment of follicular lymphoma (SABRINA): a randomised, open-label, phase 3 trial.
Andrew Davies, Francesco Merli, Biljana Mihaljević, Santiago Mercadal, Noppadol Siritanaratkul, Philippe Solal-Céligny, Axel Boehnke, Claude Berge, Magali Genevray, Artem Zharkov,[...]. Lancet Haematol 2017
68
8

Pharmacokinetics and safety of subcutaneous rituximab in follicular lymphoma (SABRINA): stage 1 analysis of a randomised phase 3 study.
Andrew Davies, Francesco Merli, Biljana Mihaljevic, Noppadol Siritanaratkul, Phillippe Solal-Céligny, Martin Barrett, Claude Berge, Beate Bittner, Axel Boehnke, Christine McIntyre,[...]. Lancet Oncol 2014
76
7

Subcutaneous vs Intravenous Trastuzumab for Patients With ERBB2-Positive Early Breast Cancer: Final Analysis of the HannaH Phase 3 Randomized Clinical Trial.
Christian Jackisch, Daniil Stroyakovskiy, Xavier Pivot, Jin Seok Ahn, Bohuslav Melichar, Shin-Cheh Chen, Christoph Meyenberg, Nedal Al-Sakaff, Dominik Heinzmann, Roberto Hegg. JAMA Oncol 2019
31
19

Subcutaneous trastuzumab (Herceptin) versus intravenous trastuzumab for the treatment of patients with HER2-positive breast cancer: A time, motion and cost assessment study in a lean operating day care oncology unit.
Wiebren A A Tjalma, Tom Van den Mooter, Tim Mertens, Valerie Bastiaens, Manon T Huizing, Konstantinos Papadimitriou. Eur J Obstet Gynecol Reprod Biol 2018
23
26

Perspectives on Subcutaneous Route of Administration as an Immunogenicity Risk Factor for Therapeutic Proteins.
Lora Hamuro, Grzegorz Kijanka, Francis Kinderman, Harald Kropshofer, De-Xiu Bu, Monica Zepeda, Vibha Jawa. J Pharm Sci 2017
33
18

Impact of injection speed and volume on perceived pain during subcutaneous injections into the abdomen and thigh: a single-centre, randomized controlled trial.
T Heise, L Nosek, S Dellweg, E Zijlstra, K A Præstmark, J Kildegaard, G Nielsen, T Sparre. Diabetes Obes Metab 2014
52
11

Pain assessment of subcutaneous injections.
J T Jørgensen, J Rømsing, M Rasmussen, J Møller-Sonnergaard, L Vang, L Musaeus. Ann Pharmacother 1996
56
10

Subcutaneous bioavailability of golimumab at 3 different injection sites in healthy subjects.
Zhenhua Xu, Qingmin Wang, Yanli Zhuang, Bart Frederick, Hong Yan, Esther Bouman-Thio, Joseph C Marini, Monica Keen, David Snead, Hugh M Davis,[...]. J Clin Pharmacol 2010
76
7




Porcine model to evaluate local tissue tolerability associated with subcutaneous delivery of protein.
D W Kang, D A Oh, G Y Fu, J M Anderson, M L Zepeda. J Pharmacol Toxicol Methods 2013
15
33

In vitro model for predicting bioavailability of subcutaneously injected monoclonal antibodies.
Hanne Kinnunen Bown, Catherine Bonn, Stefan Yohe, Daniela Bumbaca Yadav, Thomas W Patapoff, Ann Daugherty, Randall J Mrsny. J Control Release 2018
23
21


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.